

In re application of: Bruce J. Mayer, Kalle Saksela and Tomas Kirchhausen
Application No.: 10/027,770 Group: 1645
Filed: 12/20/2001 Examiner: To be assigned
For: FUSION PROTEIN AND USES THEREOF

REMARKS

Applicants have added SEQ ID NO: 5 to encompass the protein of Figure 1 (SEQ ID NO: 2) showing the site directed mutagenesis. SEQ ID NOS: 1-4 were assigned according to the originally filed application.


The amendment herein introduces no new subject matter and its entry is respectfully requested.

Please note that a two- month extension of time was filed on May 22, 2002. Applicants believe that no further extension is required. However, in the event that additional fees are required with this filing, the Commissioner is authorized to charge deficiencies to Deposit Account No. 50-0850.

Date: 6/3/02

Customer No.: 26248

Respectfully submitted,



David S. Resnick (Reg. No. 34,235)
Lana A. Shvartsman (Reg. No. P48,502)
NIXON PEABODY LLP
101 Federal Street
Boston, MA 02110
(617) 345-6057

In re application of: Bruce J. Mayer, Kari Saksela and Tomas Kirchhausen
Application No.: 10/027,770 Group: 1645
Filed: 12/20/2001 Examiner: To be assigned
For: FUSION PROTEIN AND USES THEREOF

VERSION WITH MARKINGS TO SHOW CHANGES MADE

(AMENDED) Figure 1 shows the nucleotide sequence (SEQ ID NO: 1) [and], the amino acid sequence (SEQ ID NO:2) of 3 DX, a second generation ScFv derived from monoclonal antibody 9E10, and the amino acid sequence (SEQ ID NO:5) of 3DX with site-directed mutagenesis.